The Fund supports several networks of state health policymakers to help identify, inspire, and inform policy leaders.
The Fund identifies and shares policy ideas and analysis on topics important to state health policymakers, particularly on issues related to state leadership, primary care, aging, and total costs of care.
Keep up with news and updates from the Milbank Memorial Fund. And read the latest blogs from our thought leaders, including Fund President Christopher F. Koller.
The Fund publishes The Milbank Quarterly, as well as reports, issues briefs, and case studies on topics important to health policy leaders.
The Milbank Memorial Fund is an endowed operating foundation that publishes The Milbank Quarterly, commissions projects, and convenes state health policy decision makers on issues they identify as important to population health.
As custodians of public funds, state leaders have to determine what to do about high-cost specialty drugs, such as Sovaldi, the expensive and controversial treatment for Hepatitis C. As state officials know only too well, the use of a high-priced drug like Sovaldi could result in an unplanned bottom line increase to already burdened state Medicaid budgets. What should state officials consider when making coverage decisions? What should be the pricing and coverage policies for other high-cost specialty drugs forecasted for release in the coming years?
The MMF has taken on this topic, in response to state interest and questions about high-cost breakthrough drugs. In 2014, the MMF hosted a meeting that enabled researchers and advocates to compare notes about Sovaldi. Also from 2014, read more from Christopher Koller, President of the MMF, about the states and Sovaldi and watch a video on Bio-Pharma Innovations/High Cost Drugs from the Brookings Institute Panel.
Get the Latest from the Milbank Memorial Fund
An endowed operating foundation that engages in nonpartisan analysis, collaboration, and communication, with an emphasis on state health policy.